Chan T H, Ho S S, Lai C K, Cheung S W, Chan R C, Cheng A F, Chan C H
Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong.
Chemotherapy. 1996 Mar-Apr;42(2):150-6. doi: 10.1159/000239435.
A randomised double-blind controlled clinical trial was conducted to compare oral ciprofloxacin (500 mg b.d.) and amoxycillin (1 g t.d.s.) in the treatment of infective exacerbations of bronchiectasis. The commonest organism isolated from sputum was Pseudomonas aeruginosa, which accounted for 34% of all positive sputum cultures. Other Pseudomonas species and Haemophilus influenzae, accounted for 19%, respectively. Ciprofloxacin produced better clinical response, a higher sputum to serum antibiotic level (mean of 0.65 in the ciprofloxacin group vs. 0.18 in amoxycillin group, p = 0.0001), broader spectrum of antibacterial activity and less side-effect. It was also better tolerated by patients. The findings suggest that ciprofloxacin is an effective treatment of infective exacerbations of bronchiectasis.
进行了一项随机双盲对照临床试验，以比较口服环丙沙星（每日两次，每次500毫克）和阿莫西林（每日三次，每次1克）治疗支气管扩张感染加重期的效果。从痰液中分离出的最常见病原体是铜绿假单胞菌，占所有阳性痰液培养物的34%。其他假单胞菌属和流感嗜血杆菌分别占19%。环丙沙星产生了更好的临床反应，痰液与血清抗生素水平更高（环丙沙星组平均值为0.65，阿莫西林组为0.18，p = 0.0001），抗菌活性谱更广，副作用更少。患者对其耐受性也更好。研究结果表明，环丙沙星是治疗支气管扩张感染加重期的有效药物。
